Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study

被引:12
|
作者
Descombes, Eric [1 ]
Martins, Filipe [1 ]
Hemett, Ould Maouloud [1 ]
Erard, Veronique [2 ]
Chuard, Christian [2 ]
机构
[1] HFR Fribourg Hop Cantonal, Dept Internal Med, Serv Nephrol, Fribourg, Switzerland
[2] HFR Fribourg Hop Cantonal, Dept Internal Med, Infect Dis Serv, Fribourg, Switzerland
来源
关键词
Hemodialysis; Beta-lactam antibiotics; Cefepime; Pharmacokinetics; DIALYSIS PATIENTS; RENAL-FUNCTION; PHARMACOKINETICS; NEUROTOXICITY; IMPAIRMENT; INFECTION; ADHERENCE; OUTCOMES; DISEASE;
D O I
10.1186/s40360-016-0048-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In hemodialysis patients, post-dialysis treatment with intravenous antibiotics permits even severe infections to be managed on an outpatient basis. Cefepime is a fourth-generation cephalosporin with a broad spectrum of action in monotherapy. We report on the pharmacokinetics of cefepime in post-dialysis therapy. Methods: Since June 2012, twelve infections were treated with post-dialysis cefepime in 9 patients on high-flux hemodialysis. The initial post-dialysis dose of cefepime was approximately 15 mg/kg. The following doses were adapted according to the trough serum levels obtained before the subsequent dialysis in order to be above the EUCAST breakpoints for susceptible organisms and above the MIC90. Residual plasma concentrations were determined before (n = 30) and after (n = 17) dialysis by liquid chromatography-mass spectrometry. Results: Overall, the mean +/- SD dose of cefepime was 920 +/- 270 mg (14.5 +/- 5.1 mg/kg), but it was significantly lower before the 48 h interval (775 +/- 210 mg or 12.7 +/- 4.5 mg/kg) compared to the 72 h interval (1125 +/- 225 mg or 17.2 +/- 4.9 mg/kg) (p < 0.05). The mean trough pre-dialysis concentrations were 10.7 +/- 3.9 mg/l and 11.3 +/- 5.6 mg/l at 48 and 72 h, respectively. These levels always largely exceeded the EUCAST susceptibility breakpoints for all the targeted bacteria (> 1 mg/l) with the exception of Pseudomonas aeruginosa (> 8 mg/l). Cefepime concentrations were higher in anuric patients compared to those with preserved diuresis (15.6 +/- 3.5 vs 9.25 +/- 3.6 mg/l; p < 0.001) and decreased on average by 81 % during dialysis (from 10.5 +/- 3.7 to 1.96 +/- 1.2 mg/l; p < 0.001). The clinical outcome of all patients was good. Conclusions: Outpatient treatment with cefepime administered post-dialysis three-times-weekly was effective and well-tolerated in our patients. According to our data, in patients infected by highly susceptible pathogens a fixed dose of cefepime of 1 g before every 48-h interval and of 1.5 g before every 72-h interval should be recommended, without need of routine monitoring of the cefepime blood levels. In patients having an infection with less susceptibles pathogens as P. aeruginosa, and particularly in those among them exhibiting residual renal function, higher initial doses are necessary (1.5 g before a 48-h interval and 2.0 g before a 72-h interval) with adaption according to the subsequent pre-dialysis trough serum levels.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study
    Eric Descombes
    Filipe Martins
    Ould Maouloud Hemett
    Veronique Erard
    Christian Chuard
    BMC Pharmacology and Toxicology, 17
  • [2] Trice weekly post-dialysis Cefepime prescription in patients on maintenance hemodialysis
    Martins, Filipe
    Hemett, Ould Maouloud
    Erard, Veronique
    Chuard, Christian
    Descombes, Eric
    SWISS MEDICAL WEEKLY, 2014, 144 : 9S - 9S
  • [3] Factors predicting post-dialysis fatigue of maintenance hemodialysis patients
    Huiwen Li
    Jinmei Yin
    Yi Dong
    Zhiwu Tian
    Renal Replacement Therapy, 9
  • [4] Factors predicting post-dialysis fatigue of maintenance hemodialysis patients
    Li, Huiwen
    Yin, Jinmei
    Dong, Yi
    Tian, Zhiwu
    RENAL REPLACEMENT THERAPY, 2023, 9 (01)
  • [5] Impact of twice- or three-times-weekly maintenance hemodialysis on patient outcomes A multicenter randomized trial
    Dai, Li
    Lu, Chan
    Liu, Jinnv
    Li, Shanshan
    Jin, Huanlin
    Chen, Fadong
    Xue, Zengqi
    Miao, Chusheng
    MEDICINE, 2020, 99 (20)
  • [6] Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study
    Tsai, Danny
    Zam, Betty B.
    Tongs, Carleigh
    Chiong, Fabian
    Sajiv, Cherian
    Pawar, Basant
    Ashok, Aadith
    Cooper, Brynley P.
    Tong, Steven Y. C.
    Janson, Sonja
    Wallis, Steven C.
    Roberts, Jason A.
    Parker, Suzanne L.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (08) : 1963 - 1973
  • [7] Post-dialysis fatigue and survival in patients on chronic hemodialysis
    Maurizio Bossola
    Anna Picca
    Tania Monteburini
    Emanuele Parodi
    Stefano Santarelli
    Stefano Cenerelli
    Vittorio Sirolli
    Mario Bonomini
    Enrico Di Stasio
    Journal of Nephrology, 2021, 34 : 2163 - 2165
  • [8] Post-dialysis fatigue and survival in patients on chronic hemodialysis
    Bossola, Maurizio
    Picca, Anna
    Monteburini, Tania
    Parodi, Emanuele
    Santarelli, Stefano
    Cenerelli, Stefano
    Sirolli, Vittorio
    Bonomini, Mario
    Di Stasio, Enrico
    JOURNAL OF NEPHROLOGY, 2021, 34 (06) : 2163 - 2165
  • [9] Influencing factors on post-dialysis fatigue in hemodialysis patients
    Han, Su-Jeong
    Kim, Hye-Won
    International Journal of u- and e- Service, Science and Technology, 2015, 8 (10) : 151 - 158
  • [10] Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
    Duke, Carleigh
    Parker, Suzanne L.
    Zam, Betty B.
    Chiong, Fabian
    Sajiv, Cherian
    Pawar, Basant
    Ashok, Aadith
    Cooper, Brynley P.
    Tong, Steven Y. C.
    Janson, Sonja
    Wallis, Steven C.
    Roberts, Jason A.
    Tsai, Danny
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024,